Skip to main content

Baculovirus vectors for gene therapy

Objective

Baculovirus (BV) Autographa californica multicapsid nuclear polyhedrosis virus is a promising new vector for gene therapy: it is inherently safe and can deliver large pieces of DNA to mammalian cells; its own genes are not transcripted in mammalian cells, and it is not known to be associated with any human disease. BV technology has been used for years for producing recombinant proteins, and thus large scale production technology is readily adaptable for the exploitation of gene therapy approaches. Also BV vectors can be used efficiently for producing other gene therapy vectors such as adeno-associated vectors. BV genome is well-known and we have developed several selective targeting approaches engineered into the virus envelope and capsid.
The BACULOGENES project aims to develop clinically suitable methods for the development, production, testing and validation of 2nd generation stabilised and selective BV vectors for the use in direct gene therapy applica! tions. Target diseases for direct in vivo gene delivery with selectively targeted BV will include muscle disorders, age-related macular degeneration and prostate cancer.
The BACULOGENES consortium consists of 8 partners from 6 countries, including pioneers in the use of BVs for mammalian gene transfer applications and 2 major established gene therapy vector producing companies in EU.
The consortium will devote its efforts not only to BV gene therapy applications, but also to the development of large scale production, downstream processing, purification, analysis methods. The quality control and validation assays, and all issues related to regulatory aspects required for the clinical exploitation of BV technology will be covered. The BACULOGENES project will strengthen the European leadership, knowledge and competitiveness in BV technology through the delivery of novel and validated efficient vectors and platform technology for the exploitation of potential clinical applications of gene therapy.

Field of science

  • /natural sciences/biological sciences/microbiology/virology
  • /medical and health sciences/clinical medicine/ophthalmology
  • /medical and health sciences/clinical medicine/cancer/prostate cancer
  • /medical and health sciences/medical biotechnology/genetic engineering/gene therapy

Call for proposal

FP6-2005-LIFESCIHEALTH-6
See other projects for this call

Funding Scheme

STREP - Specific Targeted Research Project

Coordinator

ARK THERAPEUTICS LIMITED
Address
79 New Cavendish Street
London
United Kingdom

Participants (8)

WAGENINGEN UNIVERSITY
Netherlands
Address
Costerweg 50
9101 Wageningen
UNIVERSITY OF EASTERN FINLAND
Finland
Address
Yliopistonranta 1
1627 Kuopio
GENETHON
France
Address
1 Bis Rue De L'internationale
BP60 Evry
ALTONABIOTEC AG
Germany
Address
Lornsenstrasse 6
Hamburg
UNIVERSITY OF YORK
United Kingdom
Address
Heslington
York
ACIES SAS
France
Address
69 Rue De La République
Lyon
PROJETS ET RESEAUX DE RECHERCHE SAS
France
Address
69 Rue De La République
Lyon
INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA
Portugal
Address
Ean - Av. República Qta Do Marquês
Oeiras